Spectral Medical Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments
30 November 2021 - 2:00PM
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:
EDT) and its wholly-owned subsidiary Dialco Medical Inc.
(“Dialco”), today announced that it will host a conference
call at 2:00 PM EST on Thursday, December 2, 2021, to provide a
clinical update and discuss the latest business developments.
The conference call will be available via telephone by dialing
toll free 877-407-0789 for U.S. callers or for international
callers +1 201-689-8562. A webcast of the call may be accessed at
https://viavid.webcasts.com/starthere.jsp?ei=1517076&tp_key=36dec0df72
or on the Company’s Investor Events section of the website here.
The conference call will be led by Chris Seto, Chief Executive
Officer, Dr. John A. Kellum, Chief Medical Officer, and Debra M.
Foster, Vice President, Clinical Development of Spectral Medical
Inc.
Investors and other interested parties are invited to submit
questions to management prior to the call’s start via email to
edt@crescendo-ir.com.
A webcast will also be archived on the Company’s Investor Events
section and a telephone replay of the call will be available at
5:00 PM EST on December 2, 2021, through December 9, 2021, and can
be accessed by dialing 844-512-2921 for U.S. callers or +1
412-317-6671 for international callers and entering replay pin
number: 13725451.
About Spectral
Spectral is a Phase III company seeking U.S. FDA
approval for its unique product for the treatment of patients with
septic shock, Toraymyxin™ (“PMX”). PMX is a
therapeutic hemoperfusion device that removes endotoxin, which can
cause sepsis, from the bloodstream and is guided by the Company’s
Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic
for the risk of developing sepsis.
PMX has been approved for therapeutic use in
Japan and Europe, and has been used safely and effectively on more
than 300,000 patients to date. In March 2009, Spectral obtained the
exclusive development and commercial rights in the U.S. for PMX,
and in November 2010, signed an exclusive distribution agreement
for this product in Canada. Approximately 330,000 patients are
diagnosed with severe sepsis and septic shock in North America each
year.
Spectral, through its wholly owned subsidiary,
Dialco Medical Inc., is also commercializing a new set of
proprietary platforms addressing renal replacement therapy
(“RRT”) across the dialysis spectrum. SAMI is
targeting the acute RRT market, while DIMI is targeting the chronic
RRT market. Dialco is currently pursuing regulatory approval for
U.S. in-home use of DIMI, which is based on the same RRT platform
as SAMI, but will be intended for home hemodialysis use. DIMI
recently received its FDA 510k clearance for use in hospital and
clinical settings, and obtained its Health Canada license for use
within Canadian hospitals, clinics and in home.
Spectral is listed on the Toronto Stock Exchange
under the symbol EDT. For more information, please visit
www.spectraldx.com.
Forward-looking statement
Information in this news release that is not
current or historical factual information may constitute
forward-looking information within the meaning of securities laws.
Implicit in this information, particularly in respect of the future
outlook of Spectral and anticipated events or results, are
assumptions based on beliefs of Spectral's senior management as
well as information currently available to it. While these
assumptions were considered reasonable by Spectral at the time of
preparation, they may prove to be incorrect. Readers are cautioned
that actual results are subject to a number of risks and
uncertainties, including the availability of funds and resources to
pursue R&D projects, the successful and timely completion of
clinical studies, the ability of Spectral to take advantage of
business opportunities in the biomedical industry, the granting of
necessary approvals by regulatory authorities as well as general
economic, market and business conditions, and could differ
materially from what is currently expected.
The TSX has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
Contact:
Mr. Chris Seto |
Mr. Ali Mahdavi |
David Waldman/Natalya Rudman |
CEO |
Capital Markets & Investor
Relations |
US Investor Relations |
Spectral Medical Inc. |
Spinnaker Capital Markets
Inc. |
Crescendo Communications,
LLC |
416-626-3233 ext. 2004 |
416-962-3300 |
212-671-1020 |
cseto@spectraldx.com |
am@spinnakercmi.com |
edt@crescendo-ir.com |
Spectral Medical (TSX:EDT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Spectral Medical (TSX:EDT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024